UC-112

Overview

UC-112 is a XIAP inhibitor with anticancer activity. UC-112 selectively downregulates and degrades survivin via the ubiquitin-mediated proteasomal degradation pathway. UC-112 reduces XIAP levels in in vivo tumor models. UC-112 activates caspase-3 / 7 and caspase-9 , and induces cancer cell apoptosis . UC-112 is applicable to studies on melanoma, prostate cancer and cancer-related research.

Application

Products | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Cancer | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Urogenital Disease | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > IAP | Products > Signaling Pathways > Survivin | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Caspase

Product Information

• Catalog No.: HY-12842
• CAS No.: 383392-66-3
• Molecular Formula: C22H24N2O2
• Molecular Weight: 348.44
• Purity: 98.92%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (7.17 mM); Clear solution
• Availability: In-stock

Source

Original product source